Valiant Laboratories

Valiant Laboratories EBITDA

The EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Valiant Laboratories (VALIANTLAB.NS) as of Nov 4, 2026 is 26.71 M INR. In the previous year, EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) was 199.21 M INR — a change of -86.59% (lower).

EBITDA

26.71 MINR

YoY

-86.59%

Last updated:

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Valiant Laboratories is 2026 26.71 M INR. EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Valiant Laboratories was 2025 199.21 M INR. It decreases by -86.59% lower compared to the previous year.

The Valiant Laboratories EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA
Date
EBITDA
Jan 1, 2021
473.95 M INR
Jan 1, 2022
416.25 M INR
Jan 1, 2023
358.73 M INR
Jan 1, 2024
92.29 M INR
Jan 1, 2025
199.21 M INR
Jan 1, 2026
26.71 M INR
The Valiant Laboratories EBITDA history
YEAREBITDAYoY
26.71 MINR-86.59%
199.21 MINR+115.86%
92.29 MINR-74.27%
358.73 MINR-13.82%
416.25 MINR-12.17%
473.95 MINR—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valiant Laboratories Stock analysis

What does Valiant Laboratories do? Valiant Laboratories Ltd manufactures paracetamol API/bulk drug for pharmaceutical applications, targeting medical conditions such as headache, muscle ache, arthritis, back ache, toothache, cold, and fever. The company operates a single manufacturing facility at Tarapur industrial estate, approximately 150 km from Nhava Sheva Port (JNPT), producing specialty chemicals and pharma intermediates for domestic and international markets. Its subsidiary, VALIANT ADVANCED SCIENCES PRIVATE LIMITED, supports the company's operations in the pharmaceutical sector. The firm's primary revenue comes from selling paracetamol API and specialty chemicals to pharmaceutical companies and distributors globally. Manufacturing focuses on high-demand applications like pain relief and fever treatment, with products distributed across India and abroad. The company leverages its Tarapur facility's proximity to Nhava Sheva Port for efficient export logistics. Valiant Laboratories Ltd serves the pharmaceutical industry by supplying essential active ingredients, particularly paracetamol, which is widely used in over-the-counter medications. The company's manufacturing capabilities for specialty chemicals and pharma intermediates cater to both domestic and international clients seeking reliable API sources. Its single-location production model ensures focused resource allocation for consistent output quality. Valiant Laboratories is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Valiant Laboratories stock

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Valiant Laboratories is 26.71 M INR in 2026.

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Valiant Laboratories changed from 199.21 M INR to 26.71 M INR, representing a -86.59% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) Valiant Laboratories since 2006 – with annual values, charts, and detailed analysis.

EBITDA measures operating performance before the impact of financial structure, tax environment, and non-cash depreciation charges.

EBITDA = EBIT + Depreciation & Amortization

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s INR is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s Valiant Laboratories historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Valiant Laboratories

All Key Metrics — Valiant Laboratories